325 related articles for article (PubMed ID: 32647978)
21. Dermatitis Herpetiformis and Celiac Disease Increase the Risk of Bullous Pemphigoid.
Varpuluoma O; Jokelainen J; Försti AK; Timonen M; Huilaja L; Tasanen K
J Invest Dermatol; 2019 Mar; 139(3):600-604. PubMed ID: 30612975
[TBL] [Abstract][Full Text] [Related]
22. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
Kridin K; Bergman R
JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
[TBL] [Abstract][Full Text] [Related]
23. Dyshidrosiform Bullous Pemphigoid.
Cohen PR
Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33924249
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non-bullous pemphigoid.
Ben Mordehai Y; Faibish H; Astman N; Greenberger S; Barzilai A; Baum S
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):161-165. PubMed ID: 31423677
[TBL] [Abstract][Full Text] [Related]
25. Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study.
Varpuluoma O; Försti AK; Jokelainen J; Turpeinen M; Timonen M; Tasanen K; Huilaja L
J Am Acad Dermatol; 2018 Dec; 79(6):1034-1038.e5. PubMed ID: 29803903
[TBL] [Abstract][Full Text] [Related]
26. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
[TBL] [Abstract][Full Text] [Related]
27. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A.
Ren Z; Hsu DY; Brieva J; Silverberg NB; Langan SM; Silverberg JI
Br J Dermatol; 2017 Jan; 176(1):87-99. PubMed ID: 27343837
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
Zhang Y; Xu Q; Chen L; Chen J; Zhang J; Zou Y; Gong T; Ji C
Front Immunol; 2021; 12():738907. PubMed ID: 34721404
[TBL] [Abstract][Full Text] [Related]
29. Comorbidity in bullous pemphigoid: up-date and clinical implications.
Huttelmaier J; Benoit S; Goebeler M
Front Immunol; 2023; 14():1196999. PubMed ID: 37457698
[TBL] [Abstract][Full Text] [Related]
30. Failure of initial disease control in bullous pemphigoid: a retrospective study of hospitalized patients in a single tertiary center.
Kremer N; Zeeli T; Sprecher E; Geller S
Int J Dermatol; 2017 Oct; 56(10):1010-1016. PubMed ID: 28856675
[TBL] [Abstract][Full Text] [Related]
31. Bullous pemphigoid.
Khandpur S; Verma P
Indian J Dermatol Venereol Leprol; 2011; 77(4):450-5. PubMed ID: 21727692
[TBL] [Abstract][Full Text] [Related]
32. Associations of pemphigus or pemphigoid with autoimmune disorders in US adult inpatients.
Narla S; Silverberg JI
J Am Acad Dermatol; 2020 Mar; 82(3):586-595. PubMed ID: 31319089
[TBL] [Abstract][Full Text] [Related]
33. A History of Asthma Increases the Risk of Bullous Pemphigoid: Insights from a Large Population-Based Study.
Kridin K; Ludwig RJ; Tzur Bitan D; Cohen AD
Dermatology; 2021; 237(6):921-928. PubMed ID: 33640889
[TBL] [Abstract][Full Text] [Related]
34. Association between bullous pemphigoid and atopic dermatitis: a population-based case-control study in Taiwan.
Wu PC; Wu CY; Lyu YS; Chang YT; Wu CY
Arch Dermatol Res; 2023 Apr; 315(3):419-427. PubMed ID: 35834038
[TBL] [Abstract][Full Text] [Related]
35. Non-Bullous Pemphigoid: A Single-Center Retrospective Study.
Moar A; Azzolini A; Tessari G; Schena D; Girolomoni G
Dermatology; 2021; 237(6):1039-1045. PubMed ID: 33979792
[TBL] [Abstract][Full Text] [Related]
36. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.
Lee SG; Lee HJ; Yoon MS; Kim DH
JAMA Dermatol; 2019 Feb; 155(2):172-177. PubMed ID: 30624566
[TBL] [Abstract][Full Text] [Related]
37. The impact of diabetes mellitus on medical complication and mortality rates among inpatients with bullous pemphigoid.
Patel S; Ahsanuddin S; Cadwell JB; Lambert WC
Ir J Med Sci; 2022 Aug; 191(4):1669-1675. PubMed ID: 34402030
[TBL] [Abstract][Full Text] [Related]
38. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
Atzori L; Deidda S; Aste N
G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
[TBL] [Abstract][Full Text] [Related]
39. Increased Risk of Squamous Cell Carcinoma of the Skin and Lymphoma Among 5,739 Patients with Bullous Pemphigoid: A Swedish Nationwide Cohort Study.
Albadri Z; Thorslund K; Häbel H; Seifert O; Grönhagen C
Acta Derm Venereol; 2020 Oct; 100(17):adv00289. PubMed ID: 32852559
[TBL] [Abstract][Full Text] [Related]
40. Prevalence, Spectrum and Clinical Implications of Malignancies in Patients with Bullous Pemphigoid.
Baum S; Steinberg S; Tzanani I; Barzilai A; Lyakhovitsky A
Acta Derm Venereol; 2023 Mar; 103():adv00888. PubMed ID: 36916952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
